A composition (10) of a ready to use ascorbic acid injection (50) is provided. The composition includes 2.5 percentage by weight ascorbic acid (20). The composition also includes 0.00125 percentage by weight edetate disodium (30). The composition further includes 1.193 percentage by weight sodium bicarbonate (40). F...

According to an embodiment of the present disclosure, the room-temperature stable, unbuffered rocuronium injection formulation for intravenous administration comprises of 1% w/v of rocuronium bromide, a pH adjusting agent comprising hydrochloric acid at a concentration between 12.5 mMol and 20 mMol for the adjustmen...

A stabilized pharmaceutical composition of 1,4-Dihydropyridines (DHP) incorporating hydrogen atom transfer (HAT) antioxidants is disclosed. The composition comprises nicardipine hydrochloride, a pharmaceutically acceptable DHP salt, at concentrations of 0.1 mg/mL to 5 mg/mL. The HAT antioxidants, such as ascorbic ac...

According to the present invention, a stable pharmaceutical composition of Ketorolac Tromethamine injection is provided, comprising ketorolac tromethamine at a concentration of 0.5% w/v to 3.0% w/v, alcohol USP at 10.0% w/v as a co-solvent, sodium chloride USP at 0.435% w/v to 0.668% w/v as a tonicity-adjusting agen...

According to an embodiment of the present disclosure, a ready-to-use, isotonic, pH stabilized, sterile aqueous solution of polymyxin B sulfate suitable for intramuscular, intravenous and intrathecal administration comprising 1,000 units/mL to 25,0000 units/mL of Polymyxin, a tonicity adjusting agent, pH adjusting ag...